3rd Forum on Biosimilars

November 1, 2013 10:34 AM

C5Group, is organizing the 3rd C5 Forum on Biosimilars in London, UK on 5 December, 2013. 

Hear industry experts share their experience on the key regulatory, development and legal barriers that have to be overcome throughout the entire life cycle of a successful launch, including:

• Navigating the European regulatory landscape for biosimilar approval: what biosimilar producers need to know in order to obtain approval of their products
• Deciphering the EMA guidelines on monoclonal antibodies to access the lucrative mAb market
• Updating your CMC strategies in line with evolving global Biosimilar regulations and current market trends
• Practical claims drafting and patent prosecution strategies for Biosimilars and Innovators
• What defence strategies are originators utilising to curtail biosimilar competition
• Harmonising your Biosimilar development programme to obtain regulatory approval in Europe and America
• Establishing a best approach to your pricing and reimbursement strategies in order to achieve successful market access
• How successful biosimilar manufacturers have been in initiating discussion with the medical community and promoting the uptake of biosimilars

For more information or to register for the event, please check c5-online.com.

Would you like to post an event on Biosimilar News?

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!